The massive market transformation this month that some on Wall Street called a "once in a decade opportunity" might have just been a one-off technical move because of taxes.Marketsread more
The Pentagon will deploy U.S. forces to the Middle East on the heels of the attack on Saudi Arabian oil facilities, United States Secretary of Defense Mark Esper announced...Defenseread more
Iran's audacious drone and cruise missile attack on Saudi Arabia's oil producing facilities has provided a critical test yet for the Trump administration's foreign policy. A...Politicsread more
Chinese trade negotiators suddenly canceled a visit to meet U.S. farmers after they wrapped up trade talks in Washington this week.Marketsread more
Shares of MasterCard are up 46% this year, and 1120% since 2011, getting a boost from the strong U.S. consumer.Investingread more
Blackstone Executive Vice Chairman Tony James says he's less optimistic now than before that the U.S.-China trade war could be resolved, but even a smaller deal could help...World Economyread more
President Trump also said he is "not looking for a partial deal" with Beijing, moving away from his suggestion last week that he would consider an "interim deal."Politicsread more
Progress on trade talks will determine how far market will move above new highs.Trader Talk with Bob Pisaniread more
"Sure, the trade war's taking its toll on business ... it's just not taking its toll where it was supposed to," Jim Cramer says.Mad Money with Jim Cramerread more
Joe Biden called on President Donald Trump Friday to release the transcript of a call with a foreign leader that is the subject of a whistleblower complaint. Biden described...Politicsread more
Sarepta Therapeutics CEO Doug Ingram told CNBC on Wednesday that accessing reimbursement from insurance companies for expensive, rare disease treatments is "always challenging."
But responding to a question about the $300,000-per-year cost for a Sarepta drug for Duchenne muscular dystrophy, Ingram defended the price tag.
"Sarepta is a small company. We have already invested $1 billion fighting Duchenne muscular dystrophy. And we're not done yet," he said on "Squawk Box."
Exondys 51 was approved for DMD on a conditional basis by the Food and Drug Administration last year, pending more testing to confirm results. It treats a mutation affecting about 13 percent of sufferers. The cost per-year is about $300,000 for a 55-pound patient. The price goes up for heavier recipients.
"This a societal question more than a Sarepta question," Ingram said. "I think it's the right decision for society to invest in finding solutions for these rare disorders."
Shares of Sarepta, which had a stock market value of $2.6 billion as of Tuesday's close on Wall Street, soared 9 percent Wednesday morning. It had risen 17 percent in premarket trading after the biopharma firm reported positive results from a clinical trial of another experimental DMD medicine. The treatment, golodirsen, targets a genetic mutation affecting about 8 percent of patients.
"Our goal is to treat 100 percent" of DMD suffers, said Ingram, who was appointed CEO of Sarepta in July. "The data that we have this morning shows we're on the right path."